The mPFS and mOS values for patients in EV-302 trial with available H-score and PD-L1 CPS values
H-score and PD-L1 CPS
mPFS
mOS
H-score < 275 (irrespective of PD-L1)
10.4 months (95% CI, 8.2–14.5)
26.1 months (95% CI, 22.3–NR)
H-score ≥ 275 (irrespective of PD-L1)
15.3 months (95% CI, 10.5–NR)
NR (95% CI, 25.6–NR)
H-score < 275 and PD-L1 CPS < 10
9.2 months (95% CI, 6.2–12.0)
22.3 months (95% CI, 17.0–NR)
H-score < 275 and PD-L1 CPS ≥ 10
10.6 months (95% CI, 8.1–NR)
31.5 months (95% CI, 25.4–NR)
H-score ≥ 275 and PD-L1 CPS < 10
11.6 months (95% CI, 8.2–22.3)
NR (95% CI, NR–NR)
H-score ≥ 275 and PD-L1 CPS ≥ 10
20.4 months (95% CI, 12.0–NR)
25.6 months (95% CI, 21.2–NR)
CPS: combined positive score; mPFS: median progression-free survival; mOS: median overall survival; PD-L1: programmed cell death protein ligand 1
Declarations
Author contributions
AJ: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. JRB: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Supervision. Both authors read and approved the submitted version.
Conflicts of interest
AJ reports receiving personal fees from RealTimeCase. JRB participates in a speaker bureaus and advisory board for EMD Serono, Pfizer, and Janssen; has received consulting fees from AstraZeneca; and has received institutional research funding from Bicycle Therapeutics, Seattle Genetics, EMD Serono, Jounce Therapeutics, and Novita.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Zibelman M, Plimack ER. Systemic therapy for bladder cancer finally comes into a new age.Future Oncol. 2016;12:2227–42. [DOI] [PubMed] [PMC]
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.N Engl J Med. 2021;384:1125–35. [DOI] [PubMed] [PMC]
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.J Clin Oncol. 2023;41:22–31. [DOI] [PubMed] [PMC]
Brown JR, Koshkin VS. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.Eur Urol Focus. 2024;10:231–3. [DOI] [PubMed]
Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA 3rd, Flaig TW, DeGraff DJ, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.Nat Rev Urol. 2020;17:259–70. [DOI] [PubMed] [PMC]
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al.; TCGA Research Network; Weinstein JN, Kwiatkowski DJ, Lerner SP. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.Cell. 2017;171:540–56.e25. [DOI] [PubMed] [PMC]
Samanta D, Almo SC. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity.Cell Mol Life Sci. 2015;72:645–58. [DOI] [PubMed] [PMC]
Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.Cancer Res. 2016;76:3003–13. [DOI] [PubMed]
Tomiyama E, Fujita K, Rodriguez Pena MDC, Taheri D, Banno E, Kato T, et al. Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.Int J Mol Sci. 2020;21:5390. [DOI] [PubMed] [PMC]
Rosenberg J, Sridhar SS, Zhang J, Smith D, Ruether D, Flaig TW, et al. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.J Clin Oncol. 2020;38:1041–9. [DOI] [PubMed] [PMC]
Klümper N, Ralser DJ, Ellinger J, Roghmann F, Albrecht J, Below E, et al. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.Clin Cancer Res. 2023;29:1496–505. [DOI] [PubMed] [PMC]
Powles TB, van der Heijden MS, Gupta S, Valderrama BP, Galsky MD, Bedke J, et al. 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV)+ pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).Ann Oncol. 2024;35:S1137–S8. [DOI]
Kotono M, Kijima T, Takada-Owada A, Okubo N, Kurashina R, Kokubun H, et al. Increased expression of ATP-binding cassette transporters in enfortumab vedotin-resistant urothelial cancer.IJU Case Rep. 2024;7:173–6. [DOI] [PubMed] [PMC]
Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.Nat Med. 2023;29:2110–20. [DOI] [PubMed] [PMC]
Black AJ, Black PC. Variant histology in bladder cancer: diagnostic and clinical implications.Transl Cancer Res. 2020;9:6565–75. [DOI] [PubMed] [PMC]
Rodler S, Eismann L, Schlenker B, Casuscelli J, Brinkmann I, Sendelhofert A, et al. Expression of Nectin-4 in Variant Histologies of Bladder Cancer and Its Prognostic Value-Need for Biomarker Testing in High-Risk Patients?Cancers (Basel). 2022;14:4411. [DOI] [PubMed] [PMC]
Hoffman-Censits JH, Lombardo KA, Parimi V, Kamanda S, Choi W, Hahn NM, et al. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.Appl Immunohistochem Mol Morphol. 2021;29:619–25. [DOI] [PubMed] [PMC]
Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Nizam A, Basu A, et al. Outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma and histology variants: Analysis of the UNITE study.J Clin Oncol. 2024;42:652. [DOI]
Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.Biochem Pharmacol. 1990;39:1941–9. [DOI] [PubMed]
Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance.Cancers (Basel). 2020;12:3323. [DOI] [PubMed] [PMC]
Krause W. Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.Cancer Drug Resist. 2019;2:82–106. [DOI] [PubMed] [PMC]
Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer.Nat Rev Cancer. 2018;18:452–64. [DOI] [PubMed] [PMC]
Chang K, Lodha R, Delavan HM, Winebaum J, Porten SP, Feng FY, et al. Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.J Clin Oncol. 2024;42:690. [DOI]
Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.Mol Cancer Ther. 2015;14:1376–84. [DOI] [PubMed] [PMC]
Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y. Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.Front Pharmacol. 2019;10:749. [DOI] [PubMed] [PMC]
Cabaud O, Berger L, Crompot E, Adélaide J, Finetti P, Garnier S, et al. Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.Mol Cancer Ther. 2022;21:1227–35. [DOI] [PubMed]
Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.Lancet. 1992;340:255–9. [DOI] [PubMed]
Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, et al. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.Clin Cancer Res. 2020;26:1034–44. [DOI] [PubMed] [PMC]
Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, et al. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.Clin Cancer Res. 2021;27:5123–30. [DOI] [PubMed] [PMC]
Klümper N, Tran NK, Zschäbitz S, Hahn O, Büttner T, Roghmann F, et al. NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.J Clin Oncol. 2024;42:2446–55. [DOI] [PubMed] [PMC]
Jindal T, Jiang C, Alhalabi O, Nguyen CB, Nizam A, Basu A, et al. 8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study.ESMO Open. 2024;9:102263. [DOI]
Jindal T, Zhang L, Jiang C, Kilari D, Alhalabi O, Nizam A, et al. Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.J Clin Oncol. 2023;41:4573. [DOI]
Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, et al. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.Front Oncol. 2023;13:1161089. [DOI] [PubMed] [PMC]
Jindal T, Jiang CY, Alhalabi O, Tsung I, Jang A, Bakaloudi DR, et al. 1988P Enfortumab vedotin (EV)+ pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study.Ann Oncol. 2024;35:S1149–50. [DOI]
Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors.Br J Cancer. 2018;118:9–16. [DOI] [PubMed] [PMC]
Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?Am Soc Clin Oncol Educ Book. 2019;39:147–64. [DOI] [PubMed]
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.Cell. 2021;184:5309–37. [DOI] [PubMed] [PMC]
Nagasaki J, Ishino T, Togashi Y. Mechanisms of resistance to immune checkpoint inhibitors.Cancer Sci. 2022;113:3303–12. [DOI] [PubMed] [PMC]
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al.; KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.N Engl J Med. 2017;376:1015–26. [DOI] [PubMed] [PMC]
Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.Lancet Oncol. 2017;18:1483–92. [DOI] [PubMed]
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al.; IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.Lancet. 2017;389:67–76. [DOI] [PubMed] [PMC]
Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity.J Immunother Cancer. 2020;8:e000266. [DOI] [PubMed] [PMC]
Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, et al. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.Clin Cancer Res. 2021;27:4287–300. [DOI] [PubMed] [PMC]
Pramod N, Dawsey S, Patgunarajah U, Lynn D, Wei W, Hobeika C, et al. Factors predictive of primary resistance (PrimRes) to immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial cancer (mUC).J Clin Oncol. 2024;42:703. [DOI]
Pramod N, Makarov V, Dawsey S, Pavicic PG, Patgunarajah U, Nair M, et al. Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.J Clin Oncol. 2024;42:670. [DOI]
Patel DM, Mateen R, Qaddour N, Carrillo A, Verschraegen C, Yang Y, et al. A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines.Cancers (Basel). 2024;16:335. [DOI]
Taylor C, Patterson KM, Friedman D, Bacot SM, Feldman GM, Wang T. Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.Cancers (Basel). 2024;16:3071. [DOI] [PubMed] [PMC]
Jang A, Lanka SM, Jaeger EB, Lieberman A, Huang M, Sartor AO, et al. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.JCO Precis Oncol. 2023;7:e2300131. [DOI] [PubMed]
Brown JR, Sonpavde GP, Calaway A, Barata PC. Circulating Tumor DNA To Assess Minimal Residual Disease: Versatile, but How Valuable?Eur Urol. 2024;86:312–4. [DOI] [PubMed]
